Given the high infiltration of CD8+PD1+ T cells in NASH, their re-activation in NASH-HCC by anti-PD1 treatment is expected to generate meaningful responses in tumor suppression. The gene discussed is PDCD1; the disease is metabolic dysfunction-associated steatohepatitis.